Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 14/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797669 | 1.00 | PDE7A (0.35) | PDE7APOLBKMT2APDE7BNPC1 | |
| SCHEMBL5981799 | 0.98 | PDE7A (0.32) | PDE7APOLBKMT2A | |
| SCHEMBL4143507 | 0.69 | KDM4E (0.34) | POLBKMT2A | |
| SCHEMBL4147779 | 0.68 | CYP2D6 (0.40) | — | |
| SCHEMBL6548604 | 0.65 | PDE7A (0.35) | PDE7APOLBKMT2APDE7B | |
| SCHEMBL24411594 | 0.63 | RAB9A (0.33) | POLBKMT2APDE7BRAB9A | |
| SCHEMBL6252259 | 0.62 | ALDH1A1 (0.32) | — | |
| SCHEMBL11491220 | 0.62 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL551553 | 0.62 | PDE7A (0.50) | PDE7APDE7B | |
| SCHEMBL22422289 | 0.62 | PDE7A (0.50) | PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0468470-A1 | Benzimidazoles, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | PDE7A 2075/4885POLB 638/4885KMT2A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.